Market Cap 1.64B
Revenue (ttm) 868.45M
Net Income (ttm) 158.69M
EPS (ttm) N/A
PE Ratio 10.52
Forward PE 8.55
Profit Margin 18.27%
Debt to Equity Ratio 0.19
Volume 490,854
Avg Vol 895,756
Day's Range N/A - N/A
Shares Out 57.84M
Stochastic %K 60%
Beta 0.88
Analysts Sell
Price Target $42.00

Company Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical tr...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 539 9800
Address:
630 West Germantown Pike, Suite 215, Plymouth Meeting, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 2:41 PM
$HRMY RSI: 23.68, MACD: -2.0962 Vol: 3.85, MA20: 31.13, MA50: 34.72 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:29 PM
$HRMY Harmony Biosciences Holdings (NASDAQ: HRMY) is gaining attention among biotech investors as its flagship narcolepsy treatment WAKIX continues driving powerful revenue growth. With nearly $870 million in annual product revenue and patient adoption rising steadily, the company is positioning itself as one of the most intriguing profitable biotech stocks in the neurological treatment space. https://biotechhealthx.com/biotech-news/is-harmony-biosciences-holdings-hrmy-a-great-buy/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 6 at 5:40 PM
$AUPH $BMRN $CPRX $HALO $HRMY Biotech stocks may be starting slow this year, but analysts believe the sector could be setting up for a powerful comeback. With massive pharmaceutical patent expirations approaching and over $1 trillion in industry capital ready for deals, these cheap biotech stocks could offer significant upside for investors searching for undervalued healthcare opportunities. https://biotechhealthx.com/biotech-news/10-cheap-biotech-stocks-to-buy-now/
0 · Reply
Estimize
Estimize Mar. 5 at 12:00 PM
Wall St is expecting 0.99 EPS for $HRMY Q1 [Reporting 05/05 BMO] http://www.estimize.com/intro/hrmy?chart=historical&metric_name=eps&utm_co
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 10:19 PM
$HRMY Current Stock Price: $28.28 Contracts to trade: $27.5 HRMY Mar 20 2026 Call Entry: $0.50 Exit: $0.90 ROI: 79% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
RunnerSignals
RunnerSignals Feb. 25 at 9:23 PM
$ENPH $HRMY $IOVA $ORCL $WDAY upgraded with smart money positioning ahead of key catalysts https://stocksrunner.com/news/2026-02-25-top-stock-upgrades-today-in-the-buzz
0 · Reply
erevnon
erevnon Feb. 25 at 11:20 AM
B of A Securities maintains Harmony Biosciences Hldgs $HRMY at Underperform and lowers the price target from $32 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
d_risk
d_risk Feb. 24 at 5:40 PM
$HRMY - Harmony Biosciences Holdings Inc - 10K - Updated Risk Factors HRMY flags new risks from expanding WAKIX into pediatric cataplexy, heavier exposure to fast-evolving AI (including cybersecurity, IP, bias and regulatory uncertainty), and mounting U.S. policy pressure on drug pricing and reimbursement under IRA, OBBBA Medicaid cuts, and emerging Trump-era MFN-style proposals. #Pharmaceuticals #PediatricCataplexy #AIRisks #DrugPricingPressure #HealthcarePolicy 🟢 Added 🟠 Removed https://d-risk.ai/HRMY/10-K/2026-02-24
0 · Reply
Itinerant
Itinerant Feb. 24 at 4:45 PM
$HRMY I suggest that the following is a key point to understanding when thinking about this earnings report of today and valuation. The reason that G&A expense was so very high in Q4 was that the company recognized $30 million of litigation expense. This was a one time expense, and therefore must be backed out when attempting to establish the ongoing annuity level of the earnings stream. That accrual appears in current liabilities, of course. Having made this adjustment, one finds that the real, ongoing earnings was $0.94 cents per share in Q4, and the real, ongoing EBITDA was $304 million at the annual rate. The company did a poor job of communicating this point. It will take the analysts some time to understand this. IMO the stock is worth $55.
0 · Reply
Quantumup
Quantumup Feb. 24 at 2:12 PM
Wolfe Research🏁 $CNTA Outperform/$40, and said, The Next Big Idea in CNS - A High-Conviction Orexin Play; Initiate with OP; $40 PT $ALKS $TAK $HRMY $ESALY Wolfe Research added, While multiple orexin-2 agonists demonstrated strong clinical data in late-stage studies, we believe CNTA's ORX750 would become the best-in-class product and generate >$3B US peak sales ➢ Key upcoming catalysts: Additional Ph2 data for higher doses expected in 1Q26, we expect good data which should move the stock up significantly (+40-50%).
0 · Reply
Latest News on HRMY
3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 5 months ago

3 Biotech Stocks I Am Accumulating

ADMA INCY SNDX XBI


Top 3 Health Care Stocks That Are Preparing To Pump In Q4

Oct 6, 2025, 6:23 AM EDT - 5 months ago

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

CRVL MLTX


OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 2:41 PM
$HRMY RSI: 23.68, MACD: -2.0962 Vol: 3.85, MA20: 31.13, MA50: 34.72 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:29 PM
$HRMY Harmony Biosciences Holdings (NASDAQ: HRMY) is gaining attention among biotech investors as its flagship narcolepsy treatment WAKIX continues driving powerful revenue growth. With nearly $870 million in annual product revenue and patient adoption rising steadily, the company is positioning itself as one of the most intriguing profitable biotech stocks in the neurological treatment space. https://biotechhealthx.com/biotech-news/is-harmony-biosciences-holdings-hrmy-a-great-buy/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 6 at 5:40 PM
$AUPH $BMRN $CPRX $HALO $HRMY Biotech stocks may be starting slow this year, but analysts believe the sector could be setting up for a powerful comeback. With massive pharmaceutical patent expirations approaching and over $1 trillion in industry capital ready for deals, these cheap biotech stocks could offer significant upside for investors searching for undervalued healthcare opportunities. https://biotechhealthx.com/biotech-news/10-cheap-biotech-stocks-to-buy-now/
0 · Reply
Estimize
Estimize Mar. 5 at 12:00 PM
Wall St is expecting 0.99 EPS for $HRMY Q1 [Reporting 05/05 BMO] http://www.estimize.com/intro/hrmy?chart=historical&metric_name=eps&utm_co
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 10:19 PM
$HRMY Current Stock Price: $28.28 Contracts to trade: $27.5 HRMY Mar 20 2026 Call Entry: $0.50 Exit: $0.90 ROI: 79% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
RunnerSignals
RunnerSignals Feb. 25 at 9:23 PM
$ENPH $HRMY $IOVA $ORCL $WDAY upgraded with smart money positioning ahead of key catalysts https://stocksrunner.com/news/2026-02-25-top-stock-upgrades-today-in-the-buzz
0 · Reply
erevnon
erevnon Feb. 25 at 11:20 AM
B of A Securities maintains Harmony Biosciences Hldgs $HRMY at Underperform and lowers the price target from $32 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
d_risk
d_risk Feb. 24 at 5:40 PM
$HRMY - Harmony Biosciences Holdings Inc - 10K - Updated Risk Factors HRMY flags new risks from expanding WAKIX into pediatric cataplexy, heavier exposure to fast-evolving AI (including cybersecurity, IP, bias and regulatory uncertainty), and mounting U.S. policy pressure on drug pricing and reimbursement under IRA, OBBBA Medicaid cuts, and emerging Trump-era MFN-style proposals. #Pharmaceuticals #PediatricCataplexy #AIRisks #DrugPricingPressure #HealthcarePolicy 🟢 Added 🟠 Removed https://d-risk.ai/HRMY/10-K/2026-02-24
0 · Reply
Itinerant
Itinerant Feb. 24 at 4:45 PM
$HRMY I suggest that the following is a key point to understanding when thinking about this earnings report of today and valuation. The reason that G&A expense was so very high in Q4 was that the company recognized $30 million of litigation expense. This was a one time expense, and therefore must be backed out when attempting to establish the ongoing annuity level of the earnings stream. That accrual appears in current liabilities, of course. Having made this adjustment, one finds that the real, ongoing earnings was $0.94 cents per share in Q4, and the real, ongoing EBITDA was $304 million at the annual rate. The company did a poor job of communicating this point. It will take the analysts some time to understand this. IMO the stock is worth $55.
0 · Reply
Quantumup
Quantumup Feb. 24 at 2:12 PM
Wolfe Research🏁 $CNTA Outperform/$40, and said, The Next Big Idea in CNS - A High-Conviction Orexin Play; Initiate with OP; $40 PT $ALKS $TAK $HRMY $ESALY Wolfe Research added, While multiple orexin-2 agonists demonstrated strong clinical data in late-stage studies, we believe CNTA's ORX750 would become the best-in-class product and generate >$3B US peak sales ➢ Key upcoming catalysts: Additional Ph2 data for higher doses expected in 1Q26, we expect good data which should move the stock up significantly (+40-50%).
0 · Reply
Itinerant
Itinerant Feb. 24 at 2:02 PM
$HRMY Large increase in Q4 G&A expense hurt the P&L a lot.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 24 at 1:17 PM
$HRMY Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.39 down -55.17% YoY • Reported revenue of $243.78M up 21.12% YoY • Harmony Biosciences reiterates 2026 WAKIX net revenue guidance between $1B and $1.04B, projecting blockbuster status in narcolepsy, reflecting the strength and durability of the pitolisant franchise.
0 · Reply
JimmyJam5350
JimmyJam5350 Feb. 24 at 1:45 AM
$HRMY meanwhile their fundamentals are great. The .markets make no sense. Theyre profitable and have no debt issues
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 23 at 7:07 PM
0 · Reply
Arcides
Arcides Feb. 23 at 5:11 PM
$HRMY about 5 years being dog shit...
0 · Reply
Hotstockinggal
Hotstockinggal Feb. 23 at 4:01 PM
$HRMY See Acorda Ampyra case for reference Anti Pharma judges
0 · Reply
Astrobro
Astrobro Feb. 23 at 5:11 AM
$HRMY This stock seems cursed. why has it only crabbed since IPO despite making good revenue? Should be like 3B MC For good commercial product and late stage pipeline. Can anyone tell me why this chart is so crabby?
0 · Reply
BigDaddyCapital
BigDaddyCapital Feb. 22 at 7:23 PM
$HRMY it’s patent infringement case against Wakix. Generics vs Harmony, this is extreme uncertainty
0 · Reply
Itinerant
Itinerant Feb. 22 at 4:41 PM
$HRMY No, it was just the failure of ZYN002 trial. This is a non event.
0 · Reply
Itinerant
Itinerant Feb. 22 at 3:49 PM
$HRMY I wonder if this sell spike is a signal from inside information. In other words, maybe the Street already knows that the earnings report will be bad. Madrigal reported a surprise bad quarter due to cost inflation. I wonder.
0 · Reply
notreload_ai
notreload_ai Feb. 20 at 9:58 PM
Truist analyst downgrades $HRMY to Hold after unfavorable trial signals on WAKIX patent challenge, warning of early generic entry risk and major franchise threat. https://notreload.xyz/harmony-biosciences-faces-patent-setback-analyst-downgrades-stock/
0 · Reply
challengers123
challengers123 Feb. 20 at 5:56 PM
$HRMY someone big dumped shares at open, probably a fund that decided this over the weekend over the Feb 10 Oveporexton news and wants out before earnings. Saw 3 big buys today though - some other big guy is picking up. Transfer of ownership between whales IMO.
0 · Reply